Document:

EXHIBIT 10.41

 

AMENDED AND RESTATED EXECUTIVE COMPENSATION
AGREEMENT

 

This Amended
and Restated Executive Compensation Agreement (“Agreement”) is entered into as of May 8, 2022, effective as of January
1, 2022 (“Amendment Date”), by and between PharmaCyte Biotech, Inc. a Nevada corporation (together with its successors
and assigns, “Company”), and Carlos A. Trujillo (“Trujillo”). The Company and Trujillo are each
referred to in this Agreement as a “Party” and collectively as “Parties.”

 

RECITALS

 

WHEREAS,
the Parties wish to amend and restate the Executive Employment Compensation Agreement between them effective as of January 1, 2015, and
amended as of December 30, 2015 and March 10, 2017 (collectively, “Prior Executive Agreement”);

 

WHEREAS,
Company desires to continue to employ Trujillo as the Chief Financial Officer of the Company in accordance with the terms and conditions
of this Agreement; and

 

WHEREAS,
Trujillo desires to continue to serve as the Chief Financial Officer of the Company in accordance with the terms and conditions of this
Agreement.

 

NOW, THEREFORE,
in consideration of the promises, mutual covenants, the above recitals, and the agreements herein set forth, and for other good and valuable
consideration, the sufficiency of which is hereby acknowledged, the Parties, intending to be legally bound, hereby agree as follows:

 

1.     
TERM. This Agreement shall be for a term commencing on the Amendment Date and ending on the third anniversary of the Amendment
Date (such period of employment “Initial Term”), followed by automatic renewals of one (1) year thereafter (each a
“Renewal Term” and, together with the Initial Term, “Term”) unless the Company or Trujillo provides
written notice of termination to the other Party at least ninety (90) days prior to the end of the Initial Term or any Renewal Term. For
the purposes hereof, the termination of this Agreement due to the Company providing written notice of termination pursuant to this Section
1 at least ninety (90) days prior to the end of the Initial Term or any Renewal Term will be deemed to be a termination of Trujillo’s
employment by Company without Cause.

 

2.      POSITION; DUTIES. Trujillo shall be
employed as: (i) a member of the Company’s Board of Directors (“Board”); and (ii) Chief Financial Officer and
shall have the authorities and responsibilities customarily associated with the status of such positions at Nasdaq listed biotechnology
companies of the same size as the Company. In his capacity as Chief Financial Officer, Trujillo shall report directly to the Chief Executive
Officer. Upon termination of Trujillo’s employment for any reason, if and to the extent requested by the Company, Trujillo shall
promptly resign from the Board and from all other positions that Trujillo then holds with the Company or any affiliate and promptly execute
all documentation for such resignations.

 

3.     
COMPENSATION AND BENEFITS. Subject in each case to the provisions of Section 4 of this Agreement in the event that his employment
hereunder terminates, Trujillo shall be entitled to the following compensation and benefits during the Term.

 

(A)  Base Salary.
The Company will pay Trujillo a base salary at an annual rate of $380,000, payable in accordance with the Company’s usual payroll
practices. The Compensation Committee of the Board may increase the base salary annually in its discretion. The annual rate of Trujillo’s
base salary as in effect from time to time is referred to herein as “Base Salary.”

 

(B)   Bonus. During the Term, Trujillo shall be eligible to receive cash incentive compensation (“Bonus”) as
determined by the Board from time to time in its sole discretion. Trujillo’s target annual incentive compensation shall be forty
percent (40%) of Trujillo’s Base Salary; and the Board may take into consideration the personal and Company objectives that are
set by the Board; provided, however, that such target Bonus and objectives will not limit the absolute discretion of the Board. To earn
incentive compensation, Trujillo must be employed by the Company, in good standing, on the day such incentive compensation is paid. Generally,
Bonuses will be paid by March 15 of the calendar year following the year to which such Bonus pertains.

 

(C) 
 Equity Compensation. During the Term, and subject to the terms and conditions of any applicable plan or other governing
documents, Trujillo shall be eligible to participate in the stock option plan and restricted stock unit plan of the Company.

 

(D) 
 Board Fees. Trujillo will not be entitled to any cash fees or other payments or equity grants for service as a director.

 

(E)   
Expense Reimbursement. The Company will reimburse Trujillo for business expenses reasonably incurred by him in the performance
of his duties with the Company, in accordance with the Company’s usual practices.

 

(F)  
 Other Benefits. Trujillo will be entitled to participate in the Company’s incentive and employee benefit plans and
programs applicable to senior executives generally as in effect from time to time, including medical, dental, vision and term life insurance,
and on a basis no less favorable than those provided to other senior executives. Trujillo will also be entitled to participate in the
Company’s 401K plan.

 

(G) 
  Vacation. Trujillo will be entitled to five (5) weeks of vacation annually (or such greater amount provided in applicable
Company policies or as may be provided to any other senior executive of the Company) to be taken at times determined by Trujillo; provided,
however, that unused vacation for one (1) year may be carried over to the next year if and to the extent that the unused vacation is attributable
to business exigencies of the Company. Trujillo will also be entitled to two (2) weeks of paid sick leave subject to the Company’s
paid sick leave policy as in effect from time to time.

 

4.     
CONSEQUENCES OF TERMINATION. The payments under this Section 4 are the only termination payments to which Trujillo is entitled
upon termination of his employment prior to the end of the Term regardless of the date during the Term in which employment is terminated.

 

(A)   Termination by Company for Cause or Termination by Trujillo without Good Reason. If Trujillo’s employment under this
Agreement is terminated prior to the end of the Term by the Company for Cause (as defined below) or by Trujillo without Good Reason (as
defined below), Trujillo will be entitled to receive the following (promptly following such termination in the case of clause (i)):

 

(i)    
Base Salary earned through the date that Trujillo’s employment hereunder terminates (“Termination Date”);
and

 

(ii) 
  unpaid expense reimbursements and vested amounts and benefits, if any, in accordance with the terms of any applicable plan, program,
corporate governance document, policy, agreement or arrangement of the Company other than the additional benefits provided to Trujillo
under the terms of this Agreement (collectively, “Accrued Compensation”).

 

“Cause”
shall mean: a good faith determination by the Board, that any of the following has occurred: (i) willful and repeated failure by Trujillo
to perform his material duties hereunder as an employee of the Company; (ii) Trujillo’s conviction of, or plea of guilty or nolo
contendere to, a felony; (iii) Trujillo’s theft or misuse of material Company property; (iv) willful misconduct or an act of moral
turpitude which is materially injurious to the Company, monetarily or otherwise; or (v) Trujillo’s material breach of this Agreement,
including, without limitation, the confidentiality obligations set forth in Section 5 below. No termination of Trujillo’s employment
will be treated as for “Cause” unless, prior to such termination, Trujillo has been provided written notice from a majority
of the Board setting forth in reasonable detail the basis on which the Company is terminating his employment for “Cause” and,
if the condition is curable, Trujillo will then have fifteen (15) days from receipt of such notice during which he may remedy the condition.
If full cure is made by Trujillo within such fifteen (15) day cure period, Cause shall be deemed not to have occurred and Trujillo’s
employment will be deemed to have continued under and subject to the provisions of this Agreement.

 

(B) 
  Termination by the Company without Cause or Termination by Trujillo for Good Reason. If Trujillo’s employment under
this Agreement is terminated prior to the end of the Term by the Company without Cause or by Trujillo for Good Reason, Trujillo will be
entitled to receive the following:

 

 (i)     Accrued Compensation;

 

(ii)    Severance equal to two times the sum of (A) Trujillo’s Base Salary in effect at the time his employment terminates and (B)
the annual bonus, if any, earned by Trujillo for the year preceding the year of termination, or, if greater,

the target bonus, if any, for the year of termination (collectively,
“Severance Payment”);

 

(iii)   Accelerated vesting of the unvested portion of any outstanding annual stock grant;

 

(iv)   
Accelerated vesting of the unvested portion of any outstanding additional option awards during the Term; and

 

(v)    The amount of COBRA premiums for his and his family’s coverage, if any, under the Company’s medical and dental plans,
in effect from time to time, and shall continue to cover Trujillo under the Company’s life insurance program, if any. Trujillo shall
be eligible to receive such medical reimbursement and life insurance coverage until the earliest of: (A) the eighteen-month anniversary
of the Termination Date; (B) the date Trujillo is no longer eligible to receive COBRA continuation coverage; and (C) the date on which
Trujillo receives or becomes eligible to receive substantially similar coverage from another employer. Notwithstanding the foregoing,
if the Company’s making payments under this Section 4(B)(v) would violate the nondiscrimination rules applicable to non-grandfathered
plans, or result in the imposition of penalties under the Patient Protection and Affordable Care Act of 2010 and the related regulations
and guidance promulgated thereunder (“PPACA”), the parties agree to reform this Section 4(B)(v) in a manner as is necessary
to comply with the PPACA.

 

Any compensation
payable pursuant to clause (i), (iii) and (iv) of this paragraph (B) shall be paid promptly after the Termination Date. Any amounts payable
pursuant to clause (ii) and (v) of this paragraph (B) shall be paid ratably for a period of twenty-four (24) months following termination
of employment as if it were salary, payable in accordance with the Company’s normal payroll practices, provided, however, that
the initial installment will begin on the 60thday following the Termination Date and will include the payments that would
otherwise have been made during such sixty (60) day period; provided that, to the extent necessary to prevent Trujillo from being subject
to adverse tax consequences under Section 409A of the Internal Revenue Code and the regulations promulgated thereunder (“Section
409A”), the first six (6) months of the continued Severance Payment shall not be paid until, and shall be paid in a single
sum payment on, the first day after the six month anniversary of the Termination Date, with the remaining monthly payments to begin on
the first day of the seventh month following the Termination Date. At the end of the period during which the Company is paying Trujillo’s
premiums for medical and dental coverage, Trujillo and any eligible family members may elect COBRA continuation coverage at his own expense
for the remainder, if any, of the required COBRA period. For the purposes hereof, if the Company elects not to extend the Term pursuant
to Section 1 above, Trujillo’s employment will be deemed to have been terminated by the Company without Cause.

 

In order to receive any payments or
benefits under clauses (ii), (iii), (iv) and (v) of this paragraph (B), Trujillo must execute and deliver to the Company a release provided
by the Company in substantially the form of Exhibit A annexed hereto and such release must become irrevocable on or before the 60th
day following the Termination Date.

 

As of the
Termination Date, except as set forth herein, Trujillo shall not be entitled to any further payments or benefits from the Company.

 

“Good
Reason” shall mean the occurrence of any of the following events without Trujillo’s express written consent: (i) a material
diminution in Trujillo’s position, title, authority, duties, working conditions or responsibilities, except for a salary reduction
implemented as part of across the board salary reductions affecting all similarly situated executives; (ii) a material breach of this
Agreement by the Company; or (iii) in connection with a Change of Control, the failure or refusal by the successor or acquiring company
(or parent thereof) to expressly assume the obligations of the Company under this Agreement. Trujillo must provide written notice to the
Company of the existence of the condition constituting the Good Reason within thirty (30) days of Trujillo’s having actual knowledge
of the existence of the condition and, if the condition is curable, the Company will then have fifteen (15) days from receipt of such
notice during which the Company may remedy the condition and not be required to pay the amounts set forth in this Section 4(B). If full
cure is made by the Company within such fifteen (15) day cure period, Good Reason shall be deemed not to have occurred and Trujillo’s
employment will be deemed to have continued under and subject to the provisions of this Agreement.

 

(C)  
Termination on Disability or Death. In the event that the employment of Trujillo terminates prior to the end of the Term
by reason of Disability (as defined below), Trujillo shall be entitled to the payments set forth in clauses (i), (ii), and (vi) of Section
4(B) including payments under the Company’s long term disability insurance plan to the extent provided for therein. The Company
may terminate Trujillo’s employment by reason of “Disability” if (and only if) Trujillo is absent from work for at
least one-hundred-eighty (180) consecutive days or for one-hundred-eighty (180) days (whether or not consecutive) in any calendar year
by reason of a physical or mental illness or injury. In the event that the employment of Trujillo terminates before the end of the Term
by reason of death, the amounts set forth in clauses (i), (iii), (iv) and (v) of Section 4(B) shall be paid to his estate and the death
benefit under the Company’s life insurance program, if any, shall be paid to his designated beneficiary, or estate in the absence
of designated beneficiary.

 

In addition,
if Trujillo’s employment under this Agreement is terminated prior to the end of the Term by reason of Disability or death, any unvested
equity compensation and any additional option awards that are granted to Trujillo shall become immediately vested and non-forfeitable
on the Termination Date and shall be transferable or exercisable for the remainder of their terms.

 

(D)  
Change of Control. If Trujillo’s employment under this Agreement is terminated prior to the end of the Term by the
Company without Cause or by Trujillo for Good Reason within two (2) years after a Change in Control or within six (6) months prior to
a Change in Control, Trujillo will be entitled to the payments and benefits set forth in Section 4(B) in a single sum cash payment on
the 60th day following his termination of employment, and otherwise subject to the terms thereof (including, without limitation,
acceleration of vesting and continuing exercisability of any equity awards). Notwithstanding the foregoing, if a Change of Control occurs
and any Company equity awards (“Transaction Date Equity Awards”) are not assumed or converted into comparable awards
with respect to stock of the acquiring or successor company (or parent thereof), then, immediately prior to the Change of Control, each
such Transaction Date Equity Award, whether or not previously vested, shall be converted into the right to receive cash or, at the election
of Trujillo, consideration in a form that is pari passu with the form of the consideration payable to the Company’s stockholders
in exchange for their shares, in an amount or having a value equal to the product of (i) the per share fair market value of the Company’s
Common Stock (based upon the consideration payable to the Company’s stockholders), less, if applicable, the per share exercise
price under such Transaction Date Equity Award, multiplied by (ii) the number of shares of Common Stock covered by such Transaction Date
Equity Award (such product being referred to as the “Award Cash-Out Amount”). The Award Cash-Out Amount with respect
to each Transaction Date Equity Award will be paid or settled at the time of or promptly (but not more than ten (10) days following the
occurrence of the Change of Control; provided, however, that, for the avoidance of doubt, if the Company’s stockholders receive
deferred and/or contingent consideration, then Trujillo will be entitled to receive such consideration as if the shares of Common Stock
covered by his Transaction Date Equity Awards had been outstanding at the time of the Change of Control.

 

“Change in Control” means any of the
following:

 

(i)    
any one person or more than one person acting as a group directly or indirectly acquires ownership of shares of the Company that,
together with the shares of the Company held by such person or group, constitutes more than thirty percent (30%) of the total fair market
value or total voting power of the shares of the Company; provided, however, that if any one person or more than one person acting as
a group is considered to own more than thirty percent (30%) of the total fair market value or total voting power of the shares of the
Company, the acquisition of additional shares by the same person or persons shall not constitute a Change of Control under this clause
(i). An increase in the percentage of shares of the Company owned by any one person or persons acting as a group as a result of a transaction
in which the Company acquires its own shares in exchange for property will be treated as an acquisition of shares of the Company by such
person or persons for purposes of this clause (i);

 

(ii)    
a majority of the members of the Company’s Board are replaced during any twelve (12) month period by directors whose appointment
or election is not endorsed by a majority of the Company’s Board prior to the date of such appointment or election; or

 

 (iii)   the sale of all or substantially all of the Company’s assets.

 

Notwithstanding
the foregoing, a Change in Control shall not occur unless such transaction constitutes a change in the ownership of the Company, a change
in effective control of the Company or a change in the ownership of a substantial portion of the Company's assets under Section 409A.

 

(E)   Section 280G. In the event that it is determined that any payments or benefits provided under this Agreement, together with
any payments or benefits to be provided under any other plan, program, arrangement or agreement, would constitute parachute payments within
the meaning of Section 280G of the Code and would, but for this Section 4(E) be subject to the excise tax imposed under Section 4999 of
the Code (or any successor provision thereto) or any similar tax imposed by state or local law or any interest or penalties with respect
to such taxes (“Excise Tax”), then the amounts of any such payments or benefits under this Agreement and such other
arrangements shall be either (a) paid in full or (b) reduced to the minimum extent necessary to ensure that no portion of the payments
or benefits is subject to the Excise Tax, whichever of the foregoing (a) or (b) results in Trujillo’s receipt on an after-tax basis
of the greatest amount of payments and benefits after taking into account the applicable federal, state, local and foreign income, employment
and excise taxes (including the Excise Tax). The Company shall cooperate in good faith with Trujillo in making such determination, including
but not limited to providing Trujillo with an estimate of any parachute payments as soon as reasonably practicable prior to an event constituting
a change in the ownership or effective control of the Company or in the ownership of a substantial portion of the assets of the Company
(within the meaning of Section 280G(b)(2)(A) of the Code). Any such reduction pursuant to this Section 4(E) shall be made in a manner
that results in the greatest economic benefit for Trujillo and is consistent with the requirements of Section 409A. Any determination
required under this Section 4(E) shall be made in writing in good faith by a nationally recognized public accounting firm selected by
the Company. The Company and Trujillo shall provide the accounting firm with such information and documents as the accounting firm may
reasonably request in order to make a determination under this Section 4(E).

 

(F)   
No Mitigation. In the event of any termination of the employment of Trujillo hereunder prior to the end of the Term, Trujillo
shall be under no obligation to seek other employment, and there shall be no offset against any amounts due him on account of any remuneration
attributable to any subsequent employment that he may obtain.

 

5.   
CONFIDENTIALITY. Trujillo recognizes and acknowledges that the continued success of the Company and its affiliates (“Company
Group”) depends upon the use and protection of a large body of confidential and proprietary information and that Trujillo will
have access to certain Confidential Information (as defined below) of the Company Group, and that such Confidential Information
constitutes valuable, special and unique property of the Company Group. “Confidential Information” will be interpreted
to include, without limitation, with respect to the Company Group (i) inventions, technology, know-how, documentation, devices, methods,
algorithms, processes, designs, manuals, analyses, improvements, research and development, non- public scientific and medical data and
methods, clinical plans, trials and strategies, technical procedures and products (ii) computer software (including operating systems,
applications and program listings), (iii) identities and lists of, individual requirements of, specific contractual arrangements with
and information about, employees, customers, vendors, distributors, independent contractors or other business relations and their confidential
information; (iv) existing or future products and services (including those under development) and related costs and pricing structures
(v) financial data, accounting and business methods and practices, marketing information and business strategies and operations (vi)
non-public information concerning legal and professional dealings, real property, tangible property and investment activities, and (vii)
similar and related confidential information and sensitive information and trade secrets. “Confidential Information” shall
not include information that (i) was in the possession of or known by Trujillo free of any obligation prior to disclosure by the Company;
(ii) is or becomes generally known to the public through disclosure in a printed publication (without breach of any of Trujillo’s
obligations hereunder); (iii) was acquired by Trujillo from a third party who independently generated such information; or (iv) is disclosed
pursuant to judicial or governmental order, provided that Trujillo promptly notifies the Company so that the Company has an adequate
opportunity to respond to such order.

 

Trujillo shall,
during and after his employment by the Company and except in connection with performing services on behalf of (or for the benefit of)
the Company or the Company Group, keep secret and retain in the strictest confidence all Confidential Information and shall not disclose
such information to any person, entity or any federal, state or local agency or authority, except as may be required by law. Notwithstanding
the foregoing, nothing contained herein shall prohibit Trujillo from filing a charge with, reporting possible violations of federal law
or regulation to, participating in any investigation by, or cooperating with any governmental agency or entity or making other disclosures
that are protected under the whistleblower provisions of applicable law or regulation.

 

Upon termination
of his employment with the Company, Trujillo shall return to the Company all confidential, proprietary and non-public materials, and any
other property of the Company, in his possession. The personal property of Trujillo, including documents relating to his benefits, compensation,
tax liabilities, personal obligations (e.g., restrictive covenants) and the like, shall not be subject to return pursuant to the preceding
sentence.

 

6.    
NON-COMPETE; NONSOLICITATION. Trujillo understands and acknowledges that the services he provides to the Company are unique
and extraordinary. Trujillo further understands and acknowledges that the Company’s ability to reserve these services for the exclusive
use of the Company is of great competitive importance and commercial value to the Company. Trujillo agrees that during his employment
by the Company and for twenty-four (24) months thereafter, he shall not, directly or indirectly, engage or be interested in (as owner,
partner, stockholder, employee, director, officer, agent, fiduciary, consultant or otherwise), with or without compensation, any line
of business in which the Company or its affiliates is actively engaged (or, in the case of cessation of employment, in which the Company
or any of its consolidated subsidiaries is then engaged at the time of such cessation). Trujillo further agrees that for twenty- four
months following the Termination Date, Trujillo will not:

 

(A)      
directly or indirectly, contact, solicit, or accept if offered to him, or direct any person, firm, corporation, association or
other entity to contact, solicit or accept if offered, any of the Company’s customers, prospective customers, or suppliers for
the purpose of providing any products and/or services that are the same as or similar to the specific products and services provided
by the Company to its customers during the Term; or

 

(B)       
solicit or accept if offered to Trujillo, with or without solicitation, on his behalf or on behalf of any other person, the services
of any person who is then a current employee of the Company (or was an employee during the six-month period preceding such solicitation),
to terminate employment or an engagement with the Company, nor hire or agree to hire any such current or former employee into employment
with Trujillo or any company, individual or other entity; provided, however, that this subpart (B) will not apply to applications for
employment from any current or former employee of the Company in response to a general solicitation that is not directed at any such current
or former employee; and provided further that this subpart (ii) shall not be deemed to preclude any future employer of Trujillo from hiring
any such current or former employee of the Company without the input or participation by Trujillo.

 

(C)       
Trujillo further represents that Trujillo’s fulfillment of the obligations set forth in this Section shall not cause Trujillo
any substantial economic hardship or render Trujillo unemployable within the industry either during or after the Restricted Period.

 

7.    
NONDISPARAGEMENT. Trujillo agrees not to, either during his employment with the Company or after his employment with the Company
has terminated, make or condone any negative, disparaging, denigrating, or derogatory remarks, either orally or in writing, about the
Company, its predecessors, successors and assigns, and any of its or their directors, officers, employees, affiliates or any shareholder,
or members of their respective families, including, without limitation, remarks that relate to their respective business operations, policies
or practices, and remarks that may be considered to be detrimental to any of their business, professional, or personal reputations. Nothing
herein shall be deemed to preclude Trujillo from testifying truthfully under oath if he is required or compelled by law to testify in
any judicial action or before any government authority or agency or from making any other legally required truthful statements or disclosures.

 

8.     
COOPERATION. Following any termination of employment, Trujillo shall cooperate with the Company in the winding up of pending
work on behalf of the Company and the orderly transfer of work to other employees. Trujillo shall also cooperate with the Company in the
defense of any action brought by any third party against the Company that relates to Trujillo’s employment by the Company. In the
event that Trujillo is subpoenaed in connection with any litigation or investigation relating to the Company or its affiliates, Trujillo
will promptly notify the Company. For the avoidance of doubt, Trujillo will be reimbursed for Trujillo’s reasonable costs and expenses
incurred by Trujillo in complying with the terms of this Section 8. Trujillo acknowledges that Trujillo’s agreement to provide cooperation
as set forth in this Section 8 is material to the Company.

 

9.     
REMEDY FOR BREACH AND MODIFICATION. Trujillo acknowledges that the provisions of this Agreement are reasonable and necessary
for the protection of the Company and that the Company may be irreparably damaged if these provisions are not specifically enforced.
Accordingly, Trujillo agrees that, in addition to any other relief or remedies available to the Company, the Company shall be entitled
to obtain appropriate temporary, preliminary and permanent injunctive or other equitable relief for the purposes of restraining Trujillo
from any actual or threatened breach of or otherwise enforcing these provisions and no bond or security will be required in connection
therewith. In addition, notwithstanding any provision in this Agreement to the contrary, if Trujillo breaches any of the provisions of
Sections 5, 6 or 7 of this Agreement at any time and such breach is either (x) willful and not inconsequential or (y) in a material respect
and not cured promptly after notice from the Company, he shall not thereafter be entitled to any payments or benefits under this Agreement,
and any option award (whether or not previously vested) will immediately terminate and the options granted pursuant thereto will no longer
be exercisable.

 

10.  
SEVERABILITY; BLUE PENCIL. If any provision of this Agreement is deemed invalid or unenforceable, such provision shall be deemed
modified and limited to the extent necessary to make it valid and enforceable. Trujillo and the Company agree that the covenants contained
in Sections 5, 6 and 7 are reasonable covenants under the circumstances and further agree that if, in the opinion of any court of competent
jurisdiction such covenants are not reasonable in any respect, such court shall have the right, power and authority to excise or modify
such provision or provisions of these covenants to such narrower scope as it determines to be enforceable and to enforce the remainder
of these covenants as so amended. Trujillo and the Company further agree that if any provision of this Agreement is determined to be unenforceable
for any reason, and such provision cannot be reformed by the court as anticipated above, such provision shall be deemed separate and severable
and the unenforceability of any such provision shall not invalidate or render unenforceable any of the remaining provisions hereof.

 

11. 
COUNTERPARTS; FACSIMILES. This Agreement may be executed in two (2) or more counterparts, each of which shall be considered
an original, but all of which together shall constitute the same instrument. Signatures delivered by facsimile or email shall be effective
for all purposes.

 

		12.	GOVERNING LAW; JURISDICTION.

 

(A)         
As a corporation incorporated in Nevada itself, the Company has an interest in having Nevada law applied to contracts with its
employees, as well as disputes with them. Applying Nevada law in this fashion affords the parties predictability as to the law to be applied,
as well as uniformity across the Company’s workforce. Consequently, this Agreement and the legal relations thus created between
the parties hereto shall be governed by, and construed and interpreted in accordance with its express terms, and otherwise in accordance
with the laws of the State of Nevada, without regard to its choice of laws or conflicts of laws principles (whether of the State of Nevada
or any other jurisdiction) that would cause the application of the law of any jurisdiction other than the State of Nevada.

 

(B)       
   Either Party may seek to enforce this Agreement in the courts of the State of Nevada. Each Party hereby consents to the non-exclusive
jurisdiction of such courts (and the appropriate appellate courts) and waives any objection to lack of jurisdiction or improper or inconvenient
venue of any such court. Process in any action or proceeding referred to in the preceding sentence may be served on either Party anywhere
in the world, whether within or without the State of Nevada. By signing below, Trujillo acknowledges that the Company has advised Trujillo
to obtain legal counsel in negotiating the terms of this Agreement including without limitation this Section 12.

 

13. 
NOTICES. Any notice or other communication made or given in connection with this Agreement may be given by counsel, shall be
in writing, and, if to a Party, shall be deemed to have been duly given when: (i) delivered to the appropriate address by hand or by nationally
recognized overnight courier service (costs prepaid); (ii) sent by electronic mail or facsimile with confirmation of transmission by the
transmitting equipment; or (iii) received or rejected by the addressee, if sent by certified mail, return receipt requested, in each case
to a Party at his or its address or facsimile number set forth below or at such other address or facsimile number as a Party may specify
by notice to the other Party:

 

To Trujillo:

 

34145 Pacific Coast Highway # 357

Dana Point, California
92629

Email: ctrujillo@PharmaCyte.com

Fax No.: (917) 595-2851

 

To the Company:

 

3960 Howard Hughes Parkway Suite 500

Las Vegas, Nevada 89169

Attention: Kenneth L. Waggoner

Chief Executive Officer

Email: kwaggoner@PharmaCyte.com

Fax
No.: (917) 595-2851

 

14.   
ENTIRE AGREEMENT; AMENDMENT. This Agreement supersedes all prior agreements between the Parties with respect to its subject
matter, including, without limitation, the Prior Executive Agreement, and cannot be changed or terminated orally. Any amendment thereof
must be in writing and signed by the Parties.

 

15.  
WAIVER. The failure of any Party or person to insist upon strict adherence to any term of this Agreement (including all attachments)
on any occasion shall not be considered a waiver or deprive that Party or person of the right thereafter to insist upon strict adherence
to that term or any other term of this Agreement (including all attachments). Any waiver must be in writing and must specifically identify
the provision(s) of this Agreement (including all attachments) being affected.

 

16.  
END OF TERM. The provisions of Sections 4, 5, 6, 7, 8, 11, 12, 13 and 14 shall continue after the end of the Term.

 

17. 
ASSIGNMENT. Except as otherwise provided in this Section 17, this Agreement shall inure to the benefit of and be binding upon
the Parties and their respective heirs, representatives, successors and assigns. This Agreement shall not be assignable by Trujillo,
and shall be assignable by the Company only to any corporation or other entity that succeeds to all, or substantially all, of the Company’s
business or assets, and that expressly assumes (or assumes by operation of law in any merger or consolidation) the Company’s obligations
hereunder; provided, however, that no such assignment shall invalidate or negate the rights of Trujillo pursuant to the provisions hereof,
including, without limitation, any such rights relating to a Change of Control. In any such event, the term “Company,”
as used herein shall mean the Company, as defined above, and any such successor or assignee. In the event of Trujillo’s death or
a judicial determination of his incapacity, references in this Agreement (including its attachments) to “Trujillo” shall
be deemed to include, as appropriate, his estate, heirs and/or legal representatives.

 

18.  
CODES. The Board has adopted a Code of Business Conduct and Ethics. Trujillo is expected to require compliance with those codes
by the Company’s employees and to comply himself.

 

19.  
DEDUCTIONS. The Company may deduct from the compensation described herein any applicable Federal, state and/or city withholding
taxes, any applicable social security contributions, and any other amounts which may be required to be deducted or withheld by the Company
pursuant to any Federal, state or city laws, rules or regulations or any election he shall have made.

 

 20. SECTION 409A. Anything in this Agreement to the contrary notwithstanding:

 

(A) 
It is intended that any amounts payable under this Agreement will either be exempt from or comply with Section 409A and all regulations,
guidance and other interpretive authority issued thereunder so as not to subject Trujillo to payment of any additional tax penalty or
interest imposed under Section 409A, and this Agreement will be interpreted on a basis consistent with such intent. References to Termination
Date or termination of employment herein mean a termination of employment that constitutes a “separation from service” within
the meaning of Section 409A.

 

(B)  
To the extent that the reimbursement of any expenses or the provision of any in- kind benefits under this Agreement is subject
to Section 409A: (i) the amount of such expenses eligible for reimbursement, or in-kind benefits to be provided during any one calendar
year shall not affect the amount of such expenses eligible for reimbursement, or in-kind benefits to be provided, in any other calendar
year (provided that this clause (i) will not be violated with regard to expenses reimbursed under any arrangement covered by Internal
Revenue Code Section 105(b) solely because such expenses are subject to a limit related to the period the arrangement is in effect); (ii)
reimbursement of any such expense shall be made by no later than December 31 of the year following the calendar year in which such expense
is incurred; and (iii) Trujillo’s right to receive such reimbursements or in-kind benefits shall not be subject to liquidation or
exchange for another benefit.

 

(C)  
Whenever payments under this Agreement are to be made in installments, each such installment shall be deemed to be a separate
payment for purposes of Section 409A. Whenever a payment under this Agreement specifies a payment period with reference to a number of
days, the actual date of payment within the specified period shall be within the sole discretion of the Company.

 

(D) 
To the extent any amount payable to Trujillo is subject to his entering into a release of claims with the Company and any such
amount is a deferral of compensation under Section 409A and which amount could be payable to Trujillo in either of two (2) taxable years,
and the timing of such payment is not subject to terms and conditions under another plan, program or agreement of the Company that otherwise
satisfies Section 409A, such payments shall be made or commence, as applicable, on January 15 (or any later date that is not earlier than
eight (8) days after the date that the release becomes irrevocable) of such later taxable year and shall include all payments that otherwise
would have been made before such date.

 

21.  
CAPTIONS. The captions in this Agreement are for convenience of reference only and shall not be given any effect in the interpretation
of this Agreement.

 

IN WITNESS WHEREOF, Trujillo and
the Company have signed this Agreement as of the date first set forth above.

 

	 	PHARMACYTE BIOTECH, INC
	 	 
	 	By:	/s/ Raymond C.F.Tong                      
	 	Name: Raymond C.F. Tong
	 	Title: Director and Chairman of the
	 	Compensation Committee
	 	 
	 	 
	 	

TRUJILLO

	 	 
	 	 
	 	By:	/s/ Carlos A. Trujillo               
	 	 
	 	 

 

 

 

 

 

 

 

 

 

 

 

    	 	1	 

     

    

 

Exhibit A

 

GENERAL RELEASE

 

		1.	GENERAL RELEASE OF ALL CLAIMS

 

The undersigned
individual (“Trujillo”) hereby irrevocably releases and forever discharges any and all known and unknown liabilities,
debts, obligations, causes of action, demands, covenants, contracts, liens, controversies and any other claim of whatsoever kind or nature
that Trujillo ever had, now has or may have in the future against PharmaCyte Biotech, Inc. (“Company”), its shareholders,
subsidiaries, affiliates, successors, assigns, officers, directors, attorneys, fiduciaries, representatives, employees, licensees, agents
and assigns (“Releasees”), to the extent arising out of or related to the performance of any services to or on behalf
of the Company or the termination of those services and, other than claims for payments, benefits or entitlements preserved by Section
4 and claims for indemnification or advancement of expenses, or coverage under the Company’s directors and officers liability insurance
of the Amended and Restated Executive Compensation Agreement dated as of April , 2022, between the Company and Trujillo (“Employment
Agreement”), including without limitation: (i) any such claims arising out of or related to any federal, state and/or local
labor or civil rights laws including, without limitation, the federal Civil Rights Acts of 1866, 1871, 1964, the Equal Pay Act, the Older
Workers Benefit Protection Act, the Rehabilitation Act, the Jury Systems Improvement Act, the Uniformed Services Employment and Reemployment
Rights Act, the Vietnam Era Veterans Readjustment Assistance Act, the National Labor Relations Act, the Worker Adjustment and Retraining
Notification Act, the Family and Medical Leave Act of 1993, the Employee Retirement Income Security Act of 1974, the Age Discrimination
in Employment Act, the Americans with Disabilities Act of 1990, the Fair Labor Standards Act of 1938, the California Fair Employment and
Housing Act, the California Labor Code, the California Constitution, the California Family Rights Act, the Nevada Fair Employment Practices
Act, the Maryland Fair Employment Practices Act, the Health Care Worker Whistleblower Protection Act, the Maryland False Claims Act, the
Maryland Parental Leave Act, the Maryland Health Working Families Act, the Maryland Wage and Hour Law, the Maryland Wage Payment and Collection
Law and the Maryland Equal Pay for Equal Work Law, all including any amendments and their respective implementing regulations; (ii) any
and all other such claims arising out of or related to any contract, any and all other federal, state or local constitutions, statutes,
rules, regulations or executive orders; or (iii) any and all such claims arising from any common law right of any kind whatsoever, including,
without limitation, any claims for any kind of tortious conduct, promissory or equitable estoppel, defamation, breach of the Company’s
policies, rules, regulations, handbooks or manuals, breach of express or implied contract or covenants of good faith, wrongful discharge
or dismissal, and/or failure to pay, in whole or part, any compensation of any kind whatsoever (collectively, “Trujillo’s
Claims”).

 

Trujillo is
not releasing any unemployment claims, workers’ compensation claims, right to COBRA benefits, or any other claim which as a matter
of law. To the extent any local, state or federal administrative agency files any claims on Trujillo’s behalf arising out of or
related to Trujillo’s employment, Trujillo waives, to the fullest extent permitted by law, to any right to any monetary or other
recovery as a result of such action, with the exception of monetary recovery on whistleblower awards.

 

Execution of
this Release by Trujillo operates as a complete bar and defense against any and all of Trujillo’s Claims against the Company and/or
the other Releasees. If Trujillo should hereafter assert any Trujillo’s Claims in any action or proceeding against the Company or
any of the Releasees, as applicable, in any forum, this Release may be raised as and shall constitute a complete bar to any such action
or proceeding and the Company and/or the Releasees shall be entitled to recover from Trujillo all costs incurred, including attorneys’
fees, in defending against any such Trujillo’s Claims.

 

 

 

    	 	2	 

     

    

 

For the purpose
of implementing a full and complete release, Trujillo expressly acknowledges that the release given in this Agreement is intended to include,
without limitation, claims that Trujillo did not know or suspect to exist in Trujillo’s favor at the time of execution of the Agreement,
regardless of whether the knowledge of such claims, or the facts upon which they might be based, would materially have affected the settlement
in this matter, and that the consideration provided under this Agreement is also for the release of those claims and contemplates extinguishment
of any such unknown claims. Trujillo further waives and relinquishes any rights and benefits which he has or may have under California
Civil Code § 1542 to the fullest extent that he may lawfully waive all such rights and benefits pertaining to the subject matter
of this Release. Civil Code § 1542 provides that a general release does not extend to claims which the creditor does not know or
suspect to exist in his favor at the time of executing the release, which if known by him must have materially affected his settlement
with the debtor. Trujillo acknowledges that he is aware that he may later discover facts in addition to or different from those which
he now knows or believes to be true with respect to the subject matter of this Release, but it is his intention to fully and finally forever
settle and release any and all claims, matters, disputes, and differences, known or unknown, suspected and unsuspected, which now exist,
may later exist or may previously have existed between the parties to the extent set forth in the first paragraph hereof, and that in
furtherance of this intention this Release shall be and remain in effect as a full and complete general release to the extent set forth
in the first paragraph herein, notwithstanding discovery or existence of any such additional or different facts.

 

		2.	OPPORTUNITY FOR REVIEW

 

This Agreement
constitutes a voluntary waiver and release of any and all rights and claims Employee may have under the Age Discrimination in Employment
Act (ADEA). Trujillo acknowledges that he has had a reasonable opportunity to review and consider the terms of this Release for a period
of at least twenty-one (21) days, that the Company has advised Trujillo, in writing, to consult an attorney prior to signing this Agreement
and that Trujillo has had the opportunity to receive counsel regarding his/ her respective rights, obligations and liabilities under this
Release and that to the extent that Trujillo has taken less than twenty-one (21) days to consider this Release, Trujillo acknowledges
that he has had sufficient time to consider this Release and to consult with counsel and that he does not desire additional time to consider
this Release. As long as Trujillo signs and delivers this Release within such twenty-one (21) daytime period, he will have seven (7) days
after such delivery to revoke his decision by delivering written notice of such revocation to the Company at Physical or Email Address.
If Trujillo does not revoke his decision during that seven (7) day period, then this Release shall become effective on the eighth day
after being delivered by Trujillo.

 

		3.	COVENANT NOT TO SUE.

 

To the maximum
extent permitted by law, Trujillo covenants not to sue or to institute or cause to be initiated, or maintain, any action in federal, state
or local agency or court against any of the Releasees, including, but not limited to, any of the claims released above.

 

		4.	BINDING EFFECT.

 

This Release is binding on Trujillo’s heirs and personal
representative.

 

		5.	NO ASSIGNMENT OF CLAIMS

 

Trujillo represents
and warrants that Trujillo has not assigned or otherwise transferred or subrogated, or purported to assign, transfer, or subrogate, to
any person or entity, any claim or portion thereof or interest therein that Trujillo may have against the Releasees.

 

 

 

    	 	3	 

     

    

 

		6.	GOVERNING LAW; MISCELLANEOUS

 

The provisions
of Sections 9, 10, 11, 12 and 14 of the Employment Agreement shall be deemed incorporated into this Release as if fully set forth herein.
Any claim or dispute arising under or relating to this Release, or the breach, termination or validity of this Release, shall be subject
to Section 12 of the Employment Agreement.

 

	 	PHARMACYTE BIOTECH, INC
	 	 
	 	By:	                                                   
	 	Name: Raymond C.F. Tong
	 	Title: Director and Chairman of the
	 	Compensation Committee
	 	 
	 	 
	 	

TRUJILLO

	 	 
	 	 
	 	By:	                                                   
	 	 
	 	 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	4Exhibit 10.42

 

 

2021 Plan

 

 

 

PHARMACYTE BIOTECH,
INC.

 

2021 EQUITY INCENTIVE
PLAN

 

Section
1.               Purpose;
Definitions. The purposes of the PharmaCyte Biotech, Inc. 2021 Equity Incentive Plan (as
amended from time to time, the “Plan”) are to: (a) enable PharmaCyte Biotech, Inc. (the “Company”)
and its affiliated companies to recruit and retain highly qualified employees, directors and consultants; (b) provide those employees,
directors and consultants with an incentive for productivity; and (c) provide those employees, directors and consultants with an opportunity
to share in the growth and value of the Company.

 

For purposes of the Plan, the following terms will
have the meanings defined below, unless the context clearly requires a different meaning:

 

(a)              
“Affiliate” means, with respect to a Person, a Person that directly or indirectly
controls, is controlled by, or is under common control with such Person.

 

(b)              
“Applicable Law” means the legal requirements relating to the administration of
and issuance of securities under stock incentive plans, including, without limitation, the requirements of state corporations law, federal,
state and foreign securities law, federal, state and foreign tax law, and the requirements of any stock exchange or quotation system upon
which the Shares may then be listed or quoted.

 

(c)              
“Award” means an award of Options, Stock Appreciation Rights, Restricted Stock,
Restricted Stock Units or Cash or Other Stock Based Awards made under this Plan.

 

(d)              
“Award Agreement” means, with respect to any particular Award, the written document
that sets forth the terms of that particular Award.

 

(e)              
“Board” means the Board of Directors of the Company, as constituted from time
to time.

 

(f)               
“Cash or Other Stock Based Award” means an award that is granted under Section
10. 

 

(g)              
“Cause” means (i) the Participant’s refusal to comply with any lawful directive
or policy of the Company which refusal is not cured by the Participant within ten (10) days of such written notice from the Company; (ii)
the Company’s determination that the Participant has committed any act of dishonesty, embezzlement, unauthorized use or disclosure
of confidential information or other intellectual property or trade secrets, common law fraud or other fraud against the Company or any
Subsidiary or Affiliate; (iii) a material breach by the Participant of any written agreement with or any fiduciary duty owed to any Company
or any Subsidiary or Affiliate; (iv) the Participant’s conviction (or the entry of a plea of a nolo contendere or equivalent plea)
of a felony or any misdemeanor involving material dishonesty or moral turpitude; or (v) the Participant’s habitual or repeated misuse
of, or habitual or repeated performance of the Participant’s duties under the influence of, alcohol, illegally obtained prescription
controlled substances or non-prescription controlled substances. Notwithstanding the foregoing, if a Participant and the Company (or any
of its Affiliates) have entered into an employment agreement, consulting agreement or other similar agreement that specifically defines
“cause,” then with respect to such Participant, “Cause” shall have the meaning defined in such other agreement.

 

 

    	 	1	 

     

    

 

(h)              
“Change in Control” shall mean the occurrence of any of the following events:
(i) any “person” (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) is or becomes a “beneficial
owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing 50%
or more of the total power to vote for the election of directors of the Company; (ii) during any twelve month period, individuals who
at the beginning of such period constitute the Board and any new director (other than a director designated by a person who has entered
into an agreement with the Company to effect a transaction described in Section 1(h)(i), Section 1(h)(iii), Section 1(h)(iv)
or Section 1(h)(v) hereof) whose election by the Board or nomination for election by the Company’s stockholders was approved
by a vote of at least a majority of the directors then still in office who either were directors at the beginning of the period of whose
election or nomination for election was previously approved, cease for any reason to constitute a majority thereof; (iii) the merger or
consolidation of the Company with another corporation where the stockholders of the Company, immediately prior to the merger or consolidation,
will not beneficially own, immediately after the merger or consolidation, shares entitling such stockholders to 50% or more of all votes
to which all stockholders of the surviving corporation would be entitled in the election of directors (without consideration of the rights
of any class of stock to elect directors by a separate class vote); (iv) the sale or other disposition of all or substantially all of
the assets of the Company; (v) a liquidation or dissolution of the Company; or (vi) such other event deemed to constitute a “Change
in Control” by the Board.

 

Notwithstanding anything in the Plan or an Award
Agreement to the contrary, to the extent necessary to comply with Section 409A of the Code, no event that, but for the application of
this paragraph, would be a Change in Control as defined in the Plan or the Award Agreement, as applicable, shall be a Change in Control
unless such event is also a “change in control event” as defined in Section 409A of the Code.

 

(i)                
“Code” means the Internal Revenue Code of 1986, as amended from time to time,
and any successor thereto.

 

(j)                
“Committee” means the committee designated by the Board to administer the Plan
under Section 2. To the extent required under Applicable Law, the Committee shall have at least two members and each member of
the Committee shall be a Non-Employee Director.

 

(k)              
“Director” means a member of the Board.

 

(l)                
“Disability” means a condition rendering a Participant Disabled.

 

(m)            
“Disabled” will have the same meaning as set forth in Section 22(e)(3) of
the Code.

 

(n)              
“Exchange Act” means the Securities Exchange Act of 1934, as amended.

 

(o)              
“Fair Market Value” means, as of any date, the value of a Share determined as
follows: (i) if the Shares are listed on any established stock exchange or a national market system, the Fair Market Value will be
the closing sales price for such stock as quoted on that system or exchange (or the system or exchange with the greatest volume of trading
in Shares) at the close of regular hours trading on the day of determination; (ii) if the Shares are regularly quoted by recognized
securities dealers but selling prices are not reported, the Fair Market Value will be the mean between the high bid and low asked prices
for Shares at the close of regular hours trading on the day of determination; or (iii) if Shares are not traded as set forth above,
the Fair Market Value will be determined in good faith by the Committee taking into consideration such factors as the Committee considers
appropriate, such determination by the Committee to be final, conclusive and binding. Notwithstanding the foregoing, in connection with
a Change in Control, Fair Market Value shall be determined in good faith by the Committee, such determination by the Committee to be final
conclusive and binding.

 

(p)              
“Incentive Stock Option” means any Option intended to be an “Incentive Stock
Option” within the meaning of Section 422 of the Code.

 

 

    	 	2	 

     

    

 

(q)              
“Non-Employee Director” will have the meaning set forth in Rule 16b-3(b)(3)(i)
promulgated by the Securities and Exchange Commission under the Exchange Act, or any successor definition adopted by the Securities and
Exchange Commission.

 

(r)               
“Non-Qualified Stock Option” means any Option that is not an Incentive Stock Option.

 

(s)               
“Option” means any option to purchase Shares (including an option to purchase
Restricted Stock, if the Committee so determines) granted pursuant to Section 5 hereof.

 

(t)                
“Parent” means, in respect of the Company, a “parent corporation”
as defined in Section 424(e) of the Code.

 

(u)              
“Participant” means an employee, consultant, Director, or other service provider
of or to the Company or any of its respective Affiliates to whom an Award is granted.

 

(v)              
“Person” means an individual, partnership, corporation, limited liability company,
trust, joint venture, unincorporated association, or other entity or association.

 

(w)            
“Restricted Stock” means Shares that are subject to restrictions pursuant to Section
8 hereof.

 

(x)              
“Restricted Stock Unit” means a right granted under and subject to restrictions
pursuant to Section 9 hereof.

 

(y)              
“Shares” means shares of the Company’s common stock, par value $.0001, subject
to substitution or adjustment as provided in Section 3(d) hereof.

 

(z)              
“Stock Appreciation Right” means a right granted under and subject to Section
6 hereof.

 

(aa)           
“Subsidiary” means, in respect of the Company, a subsidiary company as defined
in Sections 424(f) and (g) of the Code.

 

Section
2.               Administration.
The Plan shall be administered by the Committee; provided that, notwithstanding anything to the contrary herein, in its sole discretion,
the Board may at any time and from time to time exercise any and all rights and duties of the Committee under the Plan except with respect
to matters which under Applicable Law are required to be determined in the sole discretion of the Committee. Any action of the Committee
in administering the Plan shall be final, conclusive and binding on all persons, including the Company, its Subsidiaries, Affiliates,
their respective employees, the Participants, persons claiming rights from or through Participants and stockholders of the Company.

 

The Committee will have full authority to grant Awards
under this Plan and determine the terms of such Awards. Such authority will include the right to:

 

(a)              
select the individuals to whom Awards are granted (consistent with the eligibility conditions set
forth in Section 4);

 

(b)              
determine the type of Award to be granted;

 

(c)              
determine the number of Shares, if any, to be covered by each Award;

 

(d)              
establish the other terms and conditions of each Award;

 

 

    	 	3	 

     

    

 

(e)              
approve forms of agreements (including Award Agreements) for use under the Plan; and

 

(f)               
 modify or amend each Award, subject to the Participant’s consent if such modification or amendment
would materially impair such Participant’s rights.

 

The Committee will have the authority to adopt, alter
and repeal such administrative rules, guidelines and practices governing the Plan as it, from time to time, deems advisable; to interpret
the terms and provisions of the Plan and any Award issued under the Plan (and any Award Agreement); and to otherwise take any action that
may be necessary or desirable to facilitate the administration of the Plan. The Committee may correct any defect, supply any omission
or reconcile any inconsistency in the Plan or in any Award Agreement in the manner and to the extent it deems necessary to carry out the
intent of the Plan.

 

To the extent permitted by Applicable Law, the Committee
may delegate to one or more officers of the Company the authority to grant Awards to Participants who are not subject to the requirements
of Section 16 of the Exchange Act and the rules and regulations thereunder. The Committee may revoke any such allocation or delegation
at any time for any reason with or without prior notice.

 

No Director will be liable for any good faith determination,
act or omission in connection with the Plan or any Award.

 

Section
3.               Shares
Subject to the Plan.

 

(a)              
Shares Subject to the Plan. Subject to adjustment as provided in Section 3(d) of the
Plan, the maximum number of Shares that may be issued in respect of Awards under the Plan is 250,000,000 (the “Plan Limit”).
Subject to adjustment as provided in Section 3(d) of the Plan, the maximum aggregate number of Shares that may be issued under
the Plan in respect of Incentive Stock Options is 250,000,000. Any Shares issued hereunder may consist, in whole or in part, of authorized
and unissued Shares or treasury shares. Any Shares issued by the Company through the assumption or substitution of outstanding grants
in connection with the acquisition of another entity shall not reduce the maximum number of Shares available for delivery under the Plan.

 

(b)              
Effect of the Expiration or Termination of Awards. If and to the extent that an Option or
a Stock Appreciation Right expires, terminates or is canceled or forfeited for any reason without having been exercised in full, the Shares
associated with that Award will again become available for grant under the Plan. Similarly, if and to the extent an Award of Restricted
Stock or Restricted Stock Units is canceled or forfeited for any reason, the Shares subject to that Award will again become available
for grant under the Plan.

 

(c)              
 Shares Withheld in Satisfaction of Taxes or Exercise Price. Shares withheld in settlement
of a tax withholding obligation associated with an Award, or in satisfaction of the exercise price payable upon exercise of an Option,
will not again become available for grant under the Plan.

 

(d)              
Other Adjustment. In the event of any corporate event or transaction such as a merger, consolidation,
reorganization, recapitalization, stock split, reverse stock split, split up, spin-off, combination of shares, exchange of shares, stock
dividend, dividend in kind, or other like change in capital structure (other than ordinary cash dividends) to stockholders of the Company,
or other similar corporate event or transaction affecting the Shares, the Committee, to prevent dilution or enlargement of Participants’
rights under the Plan, shall, in such manner as it deems equitable, substitute or adjust, in its sole discretion, the number and kind
of shares that may be issued under the Plan or under any outstanding Awards, the number and kind of shares subject to outstanding Awards,
the exercise price, grant price or purchase price applicable to outstanding Awards, and/or any other affected terms and conditions of
this Plan or outstanding Awards.

 

(e)              
Change in Control. Notwithstanding anything to the contrary set forth in the Plan, upon or
in anticipation of any Change in Control, the Committee may, in its sole and absolute discretion and without the need for the consent
of any Participant, take one or more of the following actions contingent upon the occurrence of that Change in Control:

 

(i)                
cause any or all outstanding Awards to become vested and immediately exercisable (as applicable),
in whole or in part;

 

 

    	 	4	 

     

    

 

(ii)             
cause any outstanding Option or Stock Appreciation Right to become fully vested and immediately exercisable
for a reasonable period in advance of the Change in Control and, to the extent not exercised prior to that Change in Control, cancel that
Option or Stock Appreciation Right upon closing of the Change in Control;

 

(iii)           
cancel any unvested Award or unvested portion thereof, with or without consideration;

 

(iv)            
cancel any Award in exchange for a substitute award;

 

(v)              
redeem any Restricted Stock or Restricted Stock Unit for cash and/or other substitute consideration
with value equal to the Fair Market Value of an unrestricted Share on the date of the Change in Control;

 

(vi)            
cancel any Option or Stock Appreciation Right in exchange for cash and/or other substitute consideration
with a value equal to: (A) the number of Shares subject to that Option or Stock Appreciation Right, multiplied by (B) the difference,
if any, between the Fair Market Value on the date of the Change in Control and the exercise price of that Option or the base price of
the Stock Appreciation Right; provided, that if the Fair Market Value on the date of the Change in Control does not exceed the
exercise price of any such Option or the base price of any such Stock Appreciation Right, the Committee may cancel that Option or Stock
Appreciation Right without any payment of consideration therefor; and/or

 

(vii)         
take such other action as the Committee determines to be appropriate under the circumstances.

 

In the discretion of the Committee, any cash or substitute
consideration payable upon cancellation of an Award may be subjected to (i) vesting terms substantially identical to those that applied
to the cancelled Award immediately prior to the Change in Control, or (ii) earn-out, escrow, holdback or similar arrangements, to
the extent such arrangements are applicable to any consideration paid to stockholders in connection with the Change in Control.

 

Notwithstanding any provision of this Section
3(e), in the case of any Award subject to Section 409A of the Code, the Committee shall only be permitted to take actions under this
Section 3(e) to the extent that such actions would be consistent with the intended treatment of such Award under Section 409A of
the Code.

 

(f)               
Foreign Holders. Notwithstanding any provision of the
Plan to the contrary, in order to comply with the laws in countries other than the United States in which the Company and its Subsidiaries
operate or have employees, directors and consultants, or in order to comply with the requirements
of any foreign securities exchange or other Applicable Law, the Committee, in its sole discretion, shall have the power and authority
to: (i) modify the terms and conditions of any Award granted to employees, directors and consultants outside
the United States to comply with Applicable Law (including, without limitation, applicable foreign laws or listing requirements of any
foreign securities exchange); (ii) establish subplans and modify exercise procedures and other terms and procedures, to the extent such
actions may be necessary or advisable; provided, however, that no such subplans and/or modifications shall increase
the share limitations contained in Section 3(a); and (iii) take any action, before or after an Award is made, that it deems advisable
to obtain approval or comply with any necessary local governmental regulatory exemptions or approvals or listing requirements of any foreign
securities exchange.

 

Section
4.               Eligibility.
Employees, Directors, consultants, and other individuals who provide services to the Company or its Affiliates are eligible to be granted
Awards under the Plan; provided, however, that only employees of the Company, any Parent or a Subsidiary are eligible to be granted
Incentive Stock Options.

 

 

    	 	5	 

     

    

 

Section
5.               Options.
Options granted under the Plan may be of two types: (i) Incentive Stock Options or (ii) Non-Qualified Stock Options. The Award
Agreement shall state whether such grant is an Incentive Stock Option or a Non-Qualified Stock Option.

 

The Award Agreement evidencing any Option will incorporate
the following terms and conditions and will contain such additional terms and conditions, not inconsistent with the terms of the Plan,
as the Committee deems appropriate in its sole and absolute discretion:

 

(a)              
Option Price. The exercise price per Share under an Option will be determined by the Committee
and will not be less than 100% of the Fair Market Value on the date of the grant. However, any Incentive Stock Option granted to any Participant
who, at the time the Option is granted, owns, either directly and/or within the meaning of the attribution rules contained in Section 424(d)
of the Code, stock possessing more than 10% of the total combined voting power of all classes of stock of the Company, will have an exercise
price per Share of not less than 110% of Fair Market Value on the date of the grant.

 

(b)              
Option Term. The term of each Option will be fixed by the Committee, but no Option will be
exercisable more than 10 years after the date the Option is granted. However, any Incentive Stock Option granted to any Participant who,
at the time such Option is granted, owns, either directly and/or within the meaning of the attribution rules contained in Section 424(d)
of the Code, stock possessing more than 10% of the total combined voting power of all classes of stock of the Company, may not have a
term of more than 5 years. No Option may be exercised by any Person after expiration of the term of the Option.

 

(c)              
Exercisability. Options will vest and be exercisable at such time or times and subject to
such terms and conditions as determined by the Committee. Such terms and conditions may include the continued employment or service of
the Participant, the attainment of specified individual or corporate performance goals, or such other factors as the Committee may determine
in its sole discretion (the “Vesting Conditions”). The Committee may provide
in the terms of an Award Agreement that the Participant may exercise the unvested portion of an Option in whole or in part in exchange
for shares of Restricted Stock subject to the same vesting terms as the portion of the Option so exercised. Restricted Stock acquired
upon the exercise of an unvested Option shall be subject to such additional terms and conditions as determined by the Committee.

 

(d)              
Method of Exercise. Subject to the terms of the applicable Award Agreement, the exercisability
provisions of Section 5(c) and the termination provisions of Section 7, Options may be exercised in whole or in part from
time to time during their term by the delivery of written notice to the Company specifying the number of Shares to be purchased. Such
notice will be accompanied by payment in full of the purchase price and any taxes required to be withheld in connection with such exercise,
either by certified or bank check, or such other means as the Committee may accept. The Committee may, in its sole discretion, permit
payment of the exercise price of an Option in the form of previously acquired Shares based on the Fair Market Value of the Shares on the
date the Option is exercised or by means of a “net settlement,” whereby the Option exercise price will not be due in cash
and where the number of Shares issued upon such exercise will be equal to: (A) the product of (i) the number of Shares as to
which the Option is then being exercised, and (ii) the excess, if any, of (a) the then current Fair Market Value over (b) the
Option exercise price, divided by (B) the then current Fair Market Value.

 

An Option will not confer upon the Participant any
of the rights or privileges of a stockholder in the Company unless and until the Participant exercises the Option in accordance with the
paragraph above and is issued Shares pursuant to such exercise.

 

(e)              
Incentive Stock Option Limitations. In the case of an Incentive Stock Option, the aggregate
Fair Market Value (determined as of the time of grant) of the Shares with respect to which Incentive Stock Options are exercisable for
the first time by the Participant during any calendar year under the Plan and/or any other plan of the Company, its Parent or any Subsidiary
will not exceed $100,000. For purposes of applying the foregoing limitation, Incentive Stock Options will be taken into account in the
order granted. To the extent any Option does not meet such limitation, that Option will be treated for all purposes as a Non-Qualified
Stock Option.

 

 

    	 	6	 

     

    

 

(f)               
Termination of Service. Unless otherwise specified in the applicable Award Agreement or as
otherwise provided by the Committee at or after the time of grant, Options will be subject to the terms of Section 7 with respect
to exercise upon or following termination of employment or other service.

 

Section
6.               Stock
Appreciation Right. Subject to the other terms of the Plan, the Committee may grant Stock
Appreciation Rights to eligible individuals. Each Stock Appreciation Right shall represent the right to receive, upon exercise, an amount
equal to the number of Shares subject to the Award that is being exercised multiplied by the excess of (i) the Fair Market Value on the
date the Award is exercised, over (ii) the base price specified in the applicable Award Agreement. Distributions may be made in cash,
Shares, or a combination of both, at the discretion of the Committee. The Award Agreement evidencing each Stock Appreciation Right shall
indicate the base price, the term and the Vesting Conditions for such Award. A Stock Appreciation Right base price may never be less than
the Fair Market Value of the underlying common stock of the Company on the date of grant of such Stock Appreciation Right. The term of
each Stock Appreciation Right will be fixed by the Committee, but no Stock Appreciation Right will be exercisable more than 10 years after
the date the Stock Appreciation Right is granted. Subject to the terms and conditions of the applicable Award Agreement, Stock Appreciation
Rights may be exercised in whole or in part from time to time during their term by the delivery of written notice to the Company specifying
the portion of the Award to be exercised. Unless otherwise specified in the applicable Award Agreement or as otherwise provided by the
Committee at or after the time of grant, Stock Appreciation Rights will be subject to the terms of Section 7 with respect to exercise
upon or following termination of employment or other service.

 

Section
7.               Termination
of Service. Unless otherwise specified with respect to a particular Option or Stock Appreciation
Right in the applicable Award Agreement or otherwise determined by the Committee, any portion of an Option or Stock Appreciation Right
that is not exercisable upon termination of service will expire immediately and automatically upon such termination and any portion of
an Option or Stock Appreciation Right that is exercisable upon termination of service will expire on the date it ceases to be exercisable
in accordance with this Section 7.

 

(a)              
Termination by Reason of Death. If a Participant’s service with the Company or any Affiliate
terminates by reason of death, any Option or Stock Appreciation Right held by such Participant may thereafter be exercised, to the extent
it was exercisable at the time of his or her death or on such accelerated basis as the Committee may determine at or after grant, by the
legal representative of the estate or by the legatee of the Participant, for a period expiring (i) at such time as may be specified
by the Committee at or after grant, or (ii) if not specified by the Committee, then 12 months from the date of death, or (iii) if
sooner than the applicable period specified under (i) or (ii) above, upon the expiration of the stated term of such Option or
Stock Appreciation Right.

 

(b)              
Termination by Reason of Disability. If a Participant’s service with the Company or
any Affiliate terminates by reason of Disability, any Option or Stock Appreciation Right held by such Participant may thereafter be exercised
by the Participant or his or her personal representative, to the extent it was exercisable at the time of termination, or on such accelerated
basis as the Committee may determine at or after grant, for a period expiring (i) at such time as may be specified by the Committee
at or after grant, or (ii) if not specified by the Committee, then 12 months from the date of termination of service, or (iii) if
sooner than the applicable period specified under (i) or (ii) above, upon the expiration of the stated term of such Option or Stock Appreciation
Right.

 

(c)              
Cause. If a Participant’s service with the Company or any Affiliate is terminated for
Cause or if a Participant resigns at a time that there was a Cause basis for such Participant’s termination: (i) any Option
or Stock Appreciation Right, or portion thereof, not already exercised will be immediately and automatically forfeited as of the date
of such termination, and (ii) any Shares for which the Company has not yet delivered share certificates will be immediately and automatically
forfeited and the Company will refund to the Participant the Option exercise price paid for such Shares, if any.

 

(d)              
Other Termination. If a Participant’s service with the Company or any Affiliate terminates
for any reason other than death, Disability or Cause, any Option or Stock Appreciation Right held by such Participant may thereafter be
exercised by the Participant, to the extent it was exercisable at the time of such termination, or on such accelerated basis as the Committee
may determine at or after grant, for a period expiring (i) at such time as may be specified by the Committee at or after grant, or
(ii) if not specified by the Committee, then 90 days from the date of termination of service, or (iii) if sooner than the applicable
period specified under (i) or (ii) above, upon the expiration of the stated term of such Option or Stock Appreciation Right.

 

 

    	 	7	 

     

    

 

Section
8.               Restricted
Stock.

 

(a)              
Issuance. Restricted Stock may be issued either alone or in conjunction with other Awards.
The Committee will determine the time or times within which Restricted Stock may be subject to forfeiture, and all other conditions of
such Awards. The purchase price for Restricted Stock may, but need not, be zero.

 

(b)              
Certificates. Upon the Award of Restricted Stock, the Committee may direct that a certificate
or certificates representing the number of Shares subject to such Award be issued to the Participant or placed in a restricted stock account
(including an electronic account) with the transfer agent and in either case designating the Participant as the registered owner. The
certificate(s), if any, representing such shares shall be physically or electronically legended, as applicable, as to sale, transfer,
assignment, pledge or other encumbrances during the Restriction Period. If physical certificates are issued, they will be held in escrow
by the Company or its designee during the Restriction Period. As a condition to any Award of Restricted Stock, the Participant may be
required to deliver to the Company a share power, endorsed in blank, relating to the Shares covered by such Award.

 

(c)              
Restrictions and Conditions. The Award Agreement evidencing the grant of any Restricted Stock
will incorporate the following terms and conditions and such additional terms and conditions, not inconsistent with the terms of the Plan,
as the Committee deems appropriate in its sole and absolute discretion:

 

(i)                
During a period commencing with the date of an Award of Restricted Stock and ending at such time
or times as specified by the Committee (the “Restriction Period”), the Participant will not be permitted to sell, transfer,
pledge, assign or otherwise encumber Restricted Stock awarded under the Plan. The Committee may condition the lapse of restrictions on
Restricted Stock upon one or more Vesting Conditions.

 

(ii)             
While any Share of Restricted Stock remains subject to restriction, the Participant will have, with
respect to the Restricted Stock, the right to vote the Shares. If any cash distributions or dividends are payable with respect to the
Restricted Stock, the Committee, in its sole discretion, may require the cash distributions or dividends to be subjected to the same Restriction
Period as is applicable to the Restricted Stock with respect to which such amounts are paid, or, if the Committee so determines, reinvested
in additional Restricted Stock to the extent Shares are available under Section 3(a) of the Plan. A Participant shall not be entitled
to interest with respect to any dividends or distributions subjected to the Restriction Period. Any distributions or dividends paid in
the form of securities with respect to Restricted Stock will be subject to the same terms and conditions as the Restricted Stock with
respect to which they were paid, including, without limitation, the same Restriction Period.

 

(iii)           
Subject to the provisions of the applicable Award Agreement or as otherwise determined by the Committee,
if a Participant’s service with the Company and its Affiliates terminates prior to the expiration of the applicable Restriction
Period, the Participant’s Restricted Stock that then remains subject to forfeiture will then be forfeited automatically.

 

Section
9.               Restricted
Stock Units. Subject to the other terms of the Plan, the Committee may grant Restricted Stock
Units to eligible individuals and may impose one or more Vesting Conditions on such units. Each Restricted Stock Unit will represent a
right to receive from the Company, upon fulfillment of any applicable conditions, an amount equal to the Fair Market Value (at the time
of the distribution) of one Share. Distributions may be made in cash, Shares, or a combination of both, at the discretion of the Committee.
The Award Agreement evidencing a Restricted Stock Unit shall set forth the Vesting Conditions and time and form of payment with respect
to such Award. The Participant shall not have any stockholder rights with respect to the Shares subject to a Restricted Stock Unit Award
until that Award vests and the Shares are actually issued thereunder; provided, however, that an Award Agreement may provide
for the inclusion of dividend equivalent payments or unit credits with respect to the Award in the discretion of the Committee. Subject
to the provisions of the applicable Award Agreement or as otherwise determined by the Committee, if a Participant’s service with
the Company terminates prior to the Restricted Stock Unit Award vesting in full, any portion of the Participant’s Restricted Stock
Units that then remain subject to forfeiture will then be forfeited automatically.

 

 

    	 	8	 

     

    

 

Section
10.           Cash
or Other Stock Based Awards. Subject to the other terms of the Plan, the Committee may grant
Cash or Other Stock Based Awards (including Awards to receive unrestricted Shares or immediate cash payments) to eligible individuals.
The Award Agreement evidencing a Cash or Other Stock Based Award shall set forth the terms and conditions of such Cash or Other Stock
Based Award, including, as applicable, the term, any exercise or purchase price, performance goals, Vesting Conditions and other terms
and conditions. Payment in respect of a Cash or Other Stock Based Award may be made in cash, Shares, or a combination of cash and Shares,
as determined by the Committee.

 

Section
11.           Amendments
and Termination. Subject to any stockholder approval
that may be required under Applicable Law, the Plan may be amended or terminated at any time or from time to time by the Board.

 

Section
12.           Prohibition
on Repricing Programs. Neither the Committee nor the Board shall (i) implement any cancellation/re-grant
program pursuant to which outstanding Options or Stock Appreciation Rights under the Plan are cancelled and new Options or Stock Appreciation
Rights are granted in replacement with a lower exercise or base price per share, (ii) cancel outstanding Options or Stock Appreciation
Rights under the Plan with exercise prices or base prices per share in excess of the then current Fair Market Value for consideration
payable in equity securities of the Company or (iii) otherwise directly reduce the exercise price or base price in effect for outstanding
Options or Stock Appreciation Rights under the Plan, without in each such instance obtaining stockholder approval.

 

Section
13.           Conditions
Upon Grant of Awards and Issuance of Shares.

 

(a)              
The implementation of the Plan, the grant of any Award and the issuance of Shares in connection with
the issuance, exercise or vesting of any Award made under the Plan shall be subject to the Company’s procurement of all approvals
and permits required by regulatory authorities having jurisdiction over the Plan, the Awards made under the Plan and the Shares issuable
pursuant to those Awards.

 

(b)              
No Shares or other assets shall be issued or delivered under the Plan unless and until there shall
have been compliance with all applicable requirements of Applicable Law.

 

Section
14.           Limits
on Transferability; Beneficiaries. No Award or other right or interest of a Participant under
the Plan shall be pledged, encumbered, or hypothecated to, or in favor of, or subject to any lien, obligation, or liability of such Participant
to, any party, other than the Company, any Subsidiary or Affiliate, or assigned or transferred by such Participant other than by will
or the laws of descent and distribution, and such Awards and rights shall be exercisable during the lifetime of the Participant only by
the Participant or his or her guardian or legal representative. Notwithstanding the foregoing, the Committee may, in its discretion, provide
that Awards or other rights or interests of a Participant granted pursuant to the Plan (other than an Incentive Stock Option) be transferable,
without consideration, to immediate family members (i.e., children, grandchildren or spouse), to trusts for the benefit of such immediate
family members and to partnerships in which such family members are the only partners. The Committee may attach to such transferability
feature such terms and conditions as it deems advisable. In addition, a Participant may, in the manner established by the Committee, designate
a beneficiary (which may be a person or a trust) to exercise the rights of the Participant, and to receive any distribution, with respect
to any Award upon the death of the Participant. A beneficiary, guardian, legal representative or other person claiming any rights under
the Plan from or through any Participant shall be subject to all terms and conditions of the Plan and any Award Agreement applicable to
such Participant, except as otherwise determined by the Committee, and to any additional restrictions deemed necessary or appropriate
by the Committee.

 

 

    	 	9	 

     

    

 

Section
15.           Withholding
of Taxes. No later than the date as of which an amount first becomes includible in the gross
income of the Participant for federal income tax purposes with respect to any Award under the Plan, the Participant will pay to the Company,
or make arrangements satisfactory to the Company regarding the payment of, any federal, state or local taxes of any kind required by law
to be withheld with respect to such amount. To the extent authorized by the Committee, the required tax withholding may be satisfied by
the withholding of Shares subject to the Award based on the Fair Market Value on the date of withholding, but in any case not in excess
of the amount determined based on the maximum statutory tax rate in the applicable jurisdiction. The obligations of the Company under
the Plan will be conditioned on such payment or arrangements and the Company will have the right to deduct any such taxes from any payment
of any kind otherwise due to the Participant.

 

Section
16.           Liability
of Company.

 

(a)              
Inability to Obtain Authority. If the Company cannot, by the exercise of commercially reasonable
efforts, obtain authority from any regulatory body having jurisdiction for the sale of any Shares under this Plan, and such authority
is deemed by the Company’s counsel to be necessary to the lawful issuance of those Shares, the Company will be relieved of any liability
for failing to issue or sell those Shares.

 

(b)              
Rights of Participants and Beneficiaries. The Company will pay all amounts payable under this
Plan only to the applicable Participant, or beneficiaries entitled thereto pursuant to this Plan. The Company will not be liable for the
debts, contracts, or engagements of any Participant or his or her beneficiaries, and rights to cash payments under this Plan may not be
taken in execution by attachment or garnishment, or by any other legal or equitable proceeding while in the hands of the Company.

 

Section
17.           General
Provisions.

 

(a)              
The Committee may require each Participant to represent to and agree with the Company in writing
that the Participant is acquiring securities of the Company for investment purposes and without a view to distribution thereof and as
to such other matters as the Committee believes are appropriate.

 

(b)              
The Awards shall be subject to the Company’s stock ownership policies, as in effect from time
to time.

 

(c)              
All certificates for Shares or other securities delivered under the Plan will be subject to such
share-transfer orders and other restrictions as the Board may deem advisable under the rules, regulations and other requirements of the
Securities Act of 1933, as amended, the Exchange Act, any stock exchange upon which the Shares are then listed, and any other Applicable
Law, and the Board may cause a legend or legends to be put on any such certificates to make appropriate reference to such restrictions.

 

(d)              
Nothing contained in the Plan will prevent the Company from adopting other or additional compensation
arrangements, subject to stockholder approval if such approval is required.

 

(e)              
Neither the adoption of the Plan nor the execution of any document in connection with the Plan will:
(i) confer upon any employee or other service provider of the Company or an Affiliate any right to continued employment or engagement
with the Company or such Affiliate, or (ii) interfere in any way with the right of the Company or such Affiliate to terminate the
employment or engagement of any of its employees or other service providers at any time.

 

(f)               
The Awards (whether vested or unvested) shall be subject to rescission, cancellation or recoupment,
in whole or in part, under any current or future “clawback” or similar policy of the Company that is applicable to the Participant.
Notwithstanding any other provisions in this Plan, any Award which is subject to recovery under any law, government regulation or stock
exchange listing requirement, will be subject to such deductions and clawback as may be required to be made pursuant to such law, government
regulation or stock exchange listing requirement.

 

 

    	 	10	 

     

    

 

Section
18.           Effective
Date of Plan. The Plan will become effective upon its approval by the stockholders of the
Company in accordance with applicable law (the “Effective Date”). 

 

Section
19.           Term
of Plan. Unless the Plan shall theretofore have been terminated in accordance with Section
11, the Plan shall terminate on the 10-year anniversary of the Effective Date, and no Awards under the Plan shall thereafter be granted.

 

Section
20.           Invalid
Provisions. In the event that any provision of this Plan is found to be invalid or otherwise
unenforceable under any Applicable Law, such invalidity or unenforceability will not be construed as rendering any other provisions contained
herein as invalid or unenforceable, and all such other provisions will be given full force and effect to the same extent as though the
invalid or unenforceable provision was not contained herein.

 

Section
21.           Governing
Law. The Plan and all Awards granted hereunder will be governed by and construed in accordance
with the laws and judicial decisions of the State of Nevada, without regard to the application of the principles of conflicts of laws.

 

Section
22.           Notices.
Any notice to be given to the Company pursuant to the provisions of this Plan must be given in writing and addressed, if to the Company,
to its principal executive office to the attention of its Chief Financial Officer (or such other Person as the Company may designate in
writing from time to time), and, if to a Participant, to the address contained in the Company’s personnel files, or at such other
address as that Participant may hereafter designate in writing to the Company. Any such notice will be deemed duly given: if delivered
personally or via recognized overnight delivery service, on the date and at the time so delivered; if sent via telecopier or email, on
the date and at the time telecopied or emailed with confirmation of delivery; or, if mailed, five (5) days after the date of mailing by
registered or certified mail.

 

 

 

    	 	11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}]]